Outpatient persons capable of providing informed consent
Minimum age of 60 years old
MINI International Neuropsychiatric Interview diagnosis of major depressive disorder, based on DSM-5 criteria
MADRS score of ≥15 (moderate/severe depression)
On stable doses of psychotropic medication, including antidepressant medication, for at least 4 weeks
Able to adhere to the intervention schedule
You may not be if
Current diagnosis of major neurocognitive disorder
Current active psychosis
Unstable medical illness, including clinical or laboratory evidence of uncompensated cardiovascular, endocrine, hematologic, hepatic, pulmonary (including bronchial asthma), or renal disease
Diagnosis of narrow angle glaucoma
Suspicious, undiagnosed skin lesions or a history of melanoma
History of myocardial infarction
Atrial, nodal, or ventricular arrhythmias
History of seizures or seizure disorder
History of peptic ulcer disease
History of allergy or other hypersensitivity to levodopa, carbidopa, or to any other ingredient in the formulation of Levocarb
Active suicidal ideation
Psychotropic medication initiation or dose change \<4 weeks prior to enrolment
Regular use of dopamine antagonist or benzodiazepines ≥2mg lorazepam equivalent per day
Unable to complete neuropsychological testing in the English language
Have a non-correctable clinically significant sensory impairment (i.e., cannot hear or see well enough to complete the neuropsychological tests)
History of falls, with ≥1 fall per week during the past 4 weeks
Clareo Health | Measuring Psychomotor Response to L-DOPA Challenge As a Biomarker for Outcomes in Late-Life Depression: a Pilot Feasibility Trial
